What medication is appropriate for a 26‑year‑old adult who screens positive for ADHD and has no history of cardiac disease, hypertension, glaucoma, or substance‑use disorder?

First-Line Medication Selection for a 26-Year-Old with ADHD

Start with a long-acting stimulant—either lisdexamfetamine (Vyvanse) 20–30 mg once daily or methylphenidate extended-release (Concerta) 18 mg once daily—because stimulants achieve 70–80% response rates and produce the largest effect sizes (≈1.0) of any ADHD medication class. 1, 2

---

Why Stimulants Are First-Line

• Stimulants (methylphenidate and amphetamines) are the gold standard for adult ADHD, supported by over 161 randomized controlled trials demonstrating effect sizes of approximately 1.0 compared with 0.7 for non-stimulants. 1, 2
• Therapeutic effects appear within days, allowing rapid assessment of efficacy, whereas non-stimulants require 2–12 weeks to reach full effect. 1, 2
• Approximately 40% of patients respond to both stimulant classes (methylphenidate and amphetamine), while another 40% respond to only one class, so if the first agent fails after proper titration, switch to the alternative stimulant class before moving to non-stimulants. 1, 2

---

Choosing Between Amphetamine and Methylphenidate

• Amphetamine-based stimulants (lisdexamfetamine, mixed amphetamine salts) are preferred for adults based on comparative efficacy studies, with 70–80% response rates. 1, 2
• Methylphenidate remains equally appropriate as first-line therapy, with response rates of 78% versus 4% placebo when dosed at approximately 1 mg/kg total daily dose. 2
• Long-acting formulations are strongly preferred because they improve adherence, provide consistent all-day symptom control, reduce rebound effects, and lower diversion potential. 1, 2

---

Specific Dosing Recommendations

Lisdexamfetamine (Vyvanse)

• Start at 20–30 mg once daily in the morning. 1, 2
• Increase by 10 mg each week based on symptom response and tolerability. 1, 2
• Maximum dose is 70 mg daily. 1, 2

Methylphenidate Extended-Release (Concerta)

• Start at 18 mg once daily in the morning (equivalent to methylphenidate 5 mg three times daily). 1, 2
• Increase by 18 mg each week until optimal symptom control is achieved. 1, 2
• Maximum recommended dose is 54–72 mg daily for adults. 1, 2

Mixed Amphetamine Salts (Adderall XR)

• Start at 10 mg once daily in the morning. 1, 2
• Increase by 5 mg weekly up to 50 mg maximum (though some patients may require up to 0.9 mg/kg or 65 mg total daily dose with clear documentation that lower doses were insufficient). 1, 2

---

Baseline Assessment Before Initiating Stimulants

• Measure blood pressure and pulse at baseline and at every dose adjustment, as stimulants typically raise systolic/diastolic pressure by 3–5 mm Hg and heart rate by 5–10 bpm. 3, 4
• Obtain a detailed personal and family cardiac history, specifically screening for sudden cardiac death in relatives younger than 50 years, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, Long QT syndrome, unexplained syncope, and cardiovascular symptoms such as chest pain or palpitations. 1, 2
• Screen for substance-use history, as active substance use shifts the treatment algorithm away from stimulants. 5, 1
• Document all prior ADHD-related treatments (medications, doses, duration, response, side effects, adherence). 5, 1

---

Monitoring During Titration

• Weekly symptom ratings using standardized ADHD scales (patient and informant reports) during the first 4–6 weeks. 1, 2
• Blood pressure and pulse at each dose adjustment, then quarterly during maintenance. 1, 2, 3
• Sleep quality and appetite changes at every visit, as these are common adverse effects. 1, 2

---

When to Consider Non-Stimulants Instead

Reserve non-stimulant medications (atomoxetine, guanfacine, clonidine) for patients who have failed ≥2 stimulant trials, experience intolerable stimulant side effects, or have an active substance-use disorder. 1, 2

Atomoxetine (Strattera)

• Target dose is 60–100 mg daily (maximum 1.4 mg/kg/day or 100 mg, whichever is lower). 1, 2
• Full therapeutic effect requires 6–12 weeks (median ≈3.7 weeks). 1, 2
• Effect size is approximately 0.7, compared with stimulants (≈1.0). 1, 2
• Provides 24-hour symptom coverage and has no abuse potential, making it useful when substance-misuse risk exists. 1, 2
• FDA black-box warning for suicidal ideation mandates baseline and regular screening. 1, 2

Extended-Release Guanfacine (Intuniv)

• Start at 1 mg once daily (preferably at bedtime due to sedation). 1, 2, 6
• Titrate by 1 mg weekly to a target of 0.05–0.12 mg/kg/day (maximum 7 mg/day). 1, 2, 6
• Effect size is approximately 0.7. 1, 2, 6
• Full clinical effect is usually observed within 2–4 weeks. 1, 2, 6
• Particularly advantageous for patients with comorbid sleep disturbances, anxiety, or tics. 1, 2, 6

Extended-Release Clonidine (Kapvay)

• Similar dosing and effect size to guanfacine (≈0.7). 1, 2, 6
• Requires twice-daily dosing, reducing adherence compared with guanfacine's once-daily regimen. 6
• Causes more sedation due to lower alpha-2A receptor specificity. 6
• Must be tapered by 0.1 mg every 3–7 days to avoid rebound hypertension; never stop abruptly. 6

---

Absolute Contraindications to Stimulants

• Concurrent use of a monoamine-oxidase inhibitor (MAOI) or within 14 days of stopping an MAOI. 1
• Active psychotic disorder or mania. 1
• Symptomatic cardiovascular disease or uncontrolled hypertension. 1, 2
• Hyperthyroidism. 1
• Glaucoma (angle-closure glaucoma is an absolute contraindication; open-angle glaucoma requires caution). 1, 7
• History of illicit stimulant abuse unless treatment is provided in a controlled setting. 1

---

Common Pitfalls to Avoid

• Do not under-dose stimulants out of fear of side effects; systematic titration protocols enable roughly 70% of patients to achieve optimal response. 1, 2
• Do not assume the first stimulant dose is sufficient; most adults require titration to doses higher than the initial dose because of individual variability. 1, 2
• Do not switch to a non-stimulant after an inadequate trial of the first stimulant until the patient has been titrated to the maximum tolerated dose and a second stimulant class has been tried. 1, 2
• Do not prescribe immediate-release methylphenidate for "as-needed" use—this approach lacks evidence, creates erratic symptom control, and fundamentally undermines treatment goals. 1, 2
• Do not discontinue effective ADHD treatment solely due to concerns about "taking medication forever", as untreated ADHD is associated with increased risk of accidents, substance abuse, criminality, and functional impairment. 2

---

Multimodal Treatment Approach

• Combine pharmacotherapy with evidence-based psychosocial interventions (e.g., ADHD-specific cognitive-behavioral therapy, psychoeducation) to achieve optimal functional outcomes. 1, 2
• Cognitive Behavioral Therapy (CBT) specifically developed for ADHD is the most extensively studied psychotherapy and has increased effectiveness when combined with medication. 1, 2

---

Cardiovascular Considerations

• Long-term ADHD medication use is associated with a modest increased risk of cardiovascular diseases, especially hypertension and arterial disease, with each 1-year increase of ADHD medication use associated with a 4% increased risk of CVD. 8
• Clinicians should regularly and consistently monitor cardiovascular signs and symptoms throughout the course of treatment. 4, 8
• Initiate or intensify antihypertensive therapy when needed for adults with hypertension, including those taking ADHD medications. 2